Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain
National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain
EMS
136 participants
May 15, 2023
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of Praga formulation in the treatment of neuropathic pain.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Praga formulation tablet
Placebo pregabalin 75mg tablet
Placebo Pregabalin 150mg tablet
Pregabalin 75mg tablet
Pregabalin 150mg tablet
Placebo Praga formulation tablet
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04666714